David E Rodríguez Fuentes

David E Rodríguez Fuentes

Auto-generated profile, based on publicly available information

David E Rodríguez Fuentes

Monterrey Nuevo Leon Tecnologico de Monterrey, School of Medicine and Health Sciences

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Archives of Medical Research
Verified
Journal Article
Open access
DRDavid E. Rodríguez-Fuentes
David E. Rodríguez-Fuentes
LFLuis E. Fernández-Garza
Luis E. Fernández-Garza
JSJohn A. Samia-Meza
John A. Samia-Meza
SBSilvia A. Barrera-Barrera
Silvia A. Barrera-Barrera
ACArnold I. Caplan
Arnold I. Caplan
HBHugo A Barrera-Saldaña
Hugo A Barrera-Saldaña
Human Mesenchymal Stem Cells (hMSCs) are multipotent stem cells capable of renewing themselves and differentiation in vitro into different kinds of tissues. In vivo hMSCs are sources of trophic factors modulating the immune system and inducing intrinsic stem cells to repair damaged tissues. Currently, there are multiple clinical trials (CT) using hMSCs for therapeutic purposes in a large number of clinical settings. The search strategy on clinicaltrials.gov has focused on the key term "Mesenchymal Stem Cells", and the inclusion and exclusion criteria were separated into two stages. Stage 1, CT on phases 1-4: location, the field of application, phase, and status. For stage 2, CT that have published outcome results: field of application, treatment, intervention model, source, preparation methods, and results. By July 2020, there were a total of 1,138 registered CT. Most studies belong to either phase 2 (61.0%) or phase 1 (30.8%); most of them focused in the fields of traumatology, neurology, cardiology, and immunology. Only 18 clinical trials had published results: the most common source of isolation was bone marrow; the treatment varied from 1-200 M hMSCs; all of them have similar preparation methods; all of them have positive results with no serious adverse effects. There appears to be a broad potential for the clinical use of hMSCs with no reported serious adverse events. There are many trials in progress, their future results will help to explore the therapeutic potential of these promising cellular sources of medicinal signals.

10 June 2024 in F1000Research
Verified
Journal Article
Open access
PDF file
DFDavid E Rodríguez Fuentes
David E Rodríguez Fuentes
KNKatiana Flores Nucamendi
Katiana Flores Nucamendi
JVJorge E. Valdez-García
Jorge E. Valdez-García
CRCuevas Díaz Duran Raquel
Cuevas Díaz Duran Raquel
VAVidal-Paredes Isaac Alejandro
Vidal-Paredes Isaac Alejandro
Judith ZavalaJudith Zavala
Judith Zavala
Background Tissue engineering research aims to address the global shortage of donated corneal tissue, yet challenges persist in clinical translation. This study assesses the pathway from basic research to clinical adoption in corneal tissue engineering. Methods Bibliometric and patent analyses were conducted using the Web of Science-Core Collection and Lens databases to identify top authors, countries, journals, publication trends, inventors, patent statuses, and affiliated companies. A quality-adjusted life year (QALY) analysis compared engineered corneal endothelium to full keratoplasty. A pilot study surveyed thirty ophthalmologist surgeons from eight Latin American countries. Results A strong upward publication trend (R2 = 0.89, p = 1.53x10^-9) in corneal endothelium engineering was observed over the past decade, led by the USA, China, and Japan. Among 614 research papers, 26 patents and 10 companies were identified. Engineered corneal endothelium showed a QALY gain of 0.74 versus 0.07 of corneal transplants. Most survey respondents (97%) expressed interest in adopting engineered corneal endothelium for transplantation if affordability, biocompatibility, and functionality were assured. Conclusions While tissue engineering offers promise in alleviating corneal scarcity, a significant gap remains between scientific advancements and clinical adoption, presenting “death valleys.” Addressing this requires more efficient navigation of the interplay between scientific progress, technology adoption, and clinical practice.

18 September 2026 in F1000Research
Verified
Journal Article
Open access
PDF file
DFDavid E Rodríguez Fuentes
David E Rodríguez Fuentes
KNKatiana Flores Nucamendi
Katiana Flores Nucamendi
JVJorge E. Valdez-García
Jorge E. Valdez-García
CRCuevas Díaz Duran Raquel
Cuevas Díaz Duran Raquel
VAVidal-Paredes Isaac Alejandro
Vidal-Paredes Isaac Alejandro
Judith ZavalaJudith Zavala
Judith Zavala
Background Corneal endothelial dysfunction is a leading cause of global blindness. The main treatment is full keratoplasty, for which access is limited due to the worldwide shortage of tissue donors. Corneal tissue engineering has shown significant progress, yet there are still challenges in the path of its clinical adoption. Objective To map the translational landscape of corneal endothelial tissue engineering by integrating evidence on scientific development, intellectual property activity, commercialization signals, health-economic considerations, and clinician perspectives. Methods A scoping review was conducted using a translational framework that combined bibliometric mapping, patent activity, identification of companies and technology development status, an exploratory scenario-based cost-utility model comparing a biosynthetic corneal endothelial construct (BCET) with donor Descemet membrane endothelial keratoplasty (DMEK), and a survey of Latin American corneal surgeons assessing perceived barriers and adoption readiness. Results A total of 614 publications met the inclusion criteria, with a sustained scientific output over the last decade. Research activity was dominated by corneal endothelial tissue engineering and cell-based replacement strategies. Patent analysis identified 26 registers, while 10 companies appeared among the papers’ affiliations. The exploratory cost-utility scenario suggested that a BCET could represent a net gain of 1.04 QALYs per patient over the 10-year time horizon. Survey responses from 30 Latin American corneal surgeons revealed high interest in adopting engineered endothelial therapies. However, manufacturing capacity, regulatory approval, reimbursement, and long-term clinical evidence were consistently identified as the principal barriers to implementation. Conclusions Corneal endothelium engineering has achieved significant scientific maturity but has seen little translational progress. Further analysis to deepen understanding of regulatory bottlenecks, along with academic approaches that support the clinical adoption of new technologies through a translational-by-design approach, could shed light on better ways for early adoption and efficient clinical translation.